4-cholesten-3-one decreases breast cancer cell viability and alters membrane raft-localized EGFR expression by reducing lipogenesis and enhancing LXR-dependent cholesterol transporters
Tóm tắt
The alteration of lipid metabolism in cancer cells is recognized as one of the most important metabolic hallmarks of cancer. Membrane rafts defined as plasma membrane microdomains enriched in cholesterol and sphingolipids serve as platforms for signaling regulation in cancer. The main purpose of this study was to evaluate the effect of the cholesterol metabolite, 4-cholesten-3-one, on lipid metabolism and membrane raft integrity in two breast cancer cell lines, MCF-7 and MDA-MB-231. Its ability to reduce cell viability and migration has also been investigated. RT-qPCR was performed to evaluate the expression of enzymes involved in lipogenesis and cholesterol synthesis, and ABCG1 and ABCA1 transporters involved in cholesterol efflux. Its effect on cell viability and migration was studied using the MTT assay, the wound healing assay and the Transwell migration assay, respectively. The effect of 4-cholesten-3-one on membrane rafts integrity was investigated by studying the protein expression of flotillin-2, a membrane raft marker, and raft-enriched EGFR by western blot. Interestingly, we found that 4-cholesten-3-one treatment decreased mRNA expression of different enzymes including ACC1, FASN, SCD1 and HMGCR. We further demonstrated that 4-cholesten-3-one increased the expression of ABCG1 and ABCA1. We also found that 4-cholesten-3-one decreased the viability of MCF-7 and MDA-MB-231 cells. This effect was neutralized after treatment with LXR inverse agonist or after LXRβ knockdown by siRNA. As a result, we also demonstrated that 4-cholesten-3-one disrupts membrane rafts and cell migration capacity. Our results show that 4-cholesten-3-one exerts promising antitumor activity by altering LXR-dependent lipid metabolism in breast cancer cells without increasing lipogenesis.
Tài liệu tham khảo
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
WHO | Breast cancer. WHO. Available from: http://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/.
Liu Q, Luo Q, Halim A, Song G. Targeting lipid metabolism of cancer cells: a promising therapeutic strategy for cancer. Cancer Lett. 2017;401:39–45.
Baenke F, Peck B, Miess H, Schulze A. Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech. 2013;6:1353–63.
Mounier C, Bouraoui L, Rassart E. Lipogenesis in cancer progression (review). Int J Oncol. 2014;45:485–92.
Santos CR, Schulze A. Lipid metabolism in cancer. FEBS J. 2012;279:2610–23.
Clendening JW, Pandyra A, Boutros PC, El Ghamrasni S, Khosravi F, Trentin GA, Martirosyan A, Hakem A, Hakem R, Jurisica I, Penn LZ. Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci U S A. 2010;107:15051–6.
Chen Y, Li P. Fatty acid metabolism and cancer development. Sci Bull. 2016;61:1473–9.
Kim KH, Lee GY, Kim JI, Ham M, Won Lee J, Kim JB. Inhibitory effect of LXR activation on cell proliferation and cell cycle progression through lipogenic activity. J Lipid Res. 2010;51:3425–33.
Flaveny CA, Griffett K, El-Gendy BE-DM, Kazantzis M, Sengupta M, Amelio AL, Chatterjee A, Walker J, Solt LA, Kamenecka TM, Burris TP. Broad anti-tumor activity of a small molecule that selectively targets the Warburg effect and lipogenesis. Cancer Cell. 2015;28:42–56.
Komati R, Spadoni D, Zheng S, Sridhar J, Riley KE, Wang G. Ligands of therapeutic utility for the liver X receptors. Mol Basel Switz. 2017;22.
El Roz A, Bard J-M, Huvelin J-M, Nazih H. LXR agonists and ABCG1-dependent cholesterol efflux in MCF-7 breast Cancer cells: relation to proliferation and apoptosis. Anticancer Res. 2012;32:3007–13.
Mollinedo F, Gajate C. Lipid rafts as major platforms for signaling regulation in cancer. Adv Biol Regul. 2015;57:130–46.
Guéguinou M, Gambade A, Félix R, Chantôme A, Fourbon Y, Bougnoux P, Weber G, Potier-Cartereau M, Vandier C. Lipid rafts, KCa/ClCa/Ca2 + channel complexes and EGFR signaling: novel targets to reduce tumor development by lipids? Biochim Biophys Acta BBA - Biomembr. 1848;2015:2603–20.
Irwin ME, Mueller KL, Bohin N, Ge Y, Boerner JL. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol. 2011;226:2316–28.
Wang X, Yang Q, Guo L, Li X-H, Zhao X-H, Song L-B, Lin H-X. Flotillin-2 is associated with breast cancer progression and poor survival outcomes. J Transl Med. 2013;11:190.
Banning A, Kurrle N, Meister M, Tikkanen R. Flotillins in receptor tyrosine kinase signaling and Cancer. Cells. 2014;3:129–49.
Cao K, Xie D, Cao P, Zou Q, Lu C, Xiao S, Zhou J, Peng X. SiRNA-mediated flotillin-2 (Flot2) downregulation inhibits cell proliferation, migration, and invasion in gastric carcinoma cells. Oncol Res. 2014;21:271–9.
Chen C-L, Wu D-C, Liu M-Y, Lin M-W, Huang H-T, Huang Y-B, Chen L-C, Chen Y-Y, Chen J-J, Yang P-H, Kao Y-C, Chen P-Y. Cholest-4-en-3-one attenuates TGF-β responsiveness by inducing TGF-β receptors degradation in Mv1Lu cells and colorectal adenocarcinoma cells. J Recept Signal Transduct Res. 2017;37:189–99.
Seo DW, Choi H-S, Lee SP, Kuver R. Oxysterols from human bile induce apoptosis of canine gallbladder epithelial cells in monolayer culture. Am J Physiol Gastrointest Liver Physiol. 2004;287:1247–56.
Wolfreys AM, Hepburn PA. Safety evaluation of phytosterol esters. Part 7. Assessment of mutagenic activity of phytosterols, phytosterol esters and the cholesterol derivative, 4-cholesten-3-one. Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc. 2002;40:461–70.
Alarif WM, Al-Lihaibi SS, Ayyad SE, Abdel-Rhman MH, Badria FA. Laurene-type sesquiterpenes from the Red Sea red alga Laurencia obtusa as potential antitumor-antimicrobial agents. Eur J Med Chem. 2012;55:462–6.
Kendel M, Wielgosz-Collin G, Bertrand S, Roussakis C, Bourgougnon N, Bedoux G. Lipid composition, fatty acids and sterols in the seaweeds Ulva armoricana, and Solieria chordalis from Brittany (France): an analysis from nutritional, chemotaxonomic, and Antiproliferative activity perspectives. Mar Drugs. 2015;13:5606–28.
Zhu Y-Z, Liu J-W, Wang X, Jeong I-H, Ahn Y-J, Zhang C-J. Anti-BACE1 and antimicrobial activities of steroidal compounds isolated from marine Urechis unicinctus. Mar Drugs. 2018;16.
Pan L, Lezama-Davila CM, Isaac-Marquez AP, Calomeni EP, Fuchs JR, Satoskar AR, Kinghorn AD. Sterols with antileishmanial activity isolated from the roots of Pentalinon andrieuxii. Phytochemistry. 2012;82:128–35.
Lin A-S, Engel S, Smith BA, Fairchild CR, Aalbersberg W, Hay ME, Kubanek J. Structure and biological evaluation of novel cytotoxic sterol glycosides from the marine red alga Peyssonnelia sp. Bioorg Med Chem. 2010;18:8264–9.
Ma J, Fu G, Wu J, Han S, Zhang L, Yang M, Yu Y, Zhang M, Lin Y, Wang Y. 4-cholesten-3-one suppresses lung adenocarcinoma metastasis by regulating translocation of HMGB1, HIF1α and Caveolin-1. Cell Death Dis. 2016;7:e2372.
Suzuki K. Anti-obesity effect of cholest-4-en-3-one, an intestinal catabolite of cholesterol, on mice. J Nutr Sci Vitaminol (Tokyo). 1993;39:537–43.
Rao Malla R, Raghu H, Rao JS. Regulation of NADPH oxidase (Nox2) by lipid rafts in breast carcinoma cells. Int J Oncol. 2010;37:1483–93.
Williams S, Bledsoe RK, Collins JL, Boggs S, Lambert MH, Miller AB, Moore J, McKee DD, Moore L, Nichols J, Parks D, Watson M, Wisely B, Willson TM. X-ray crystal structure of the liver X receptor beta ligand binding domain: regulation by a histidine-tryptophan switch. J Biol Chem. 2003;278:27138–43.
El-Gendy BE-DM, Goher SS, Hegazy LS, Arief MMH, Burris TP. Recent advances in the medicinal chemistry of liver X receptors. J Med Chem. 2018;61:10935–56.
Currie E, Schulze A, Zechner R, Walther TC, Farese RV. Cellular fatty acid metabolism and cancer. Cell Metab. 2013;18:153–61.
Zaidi N, Lupien L, Kuemmerle NB, Kinlaw WB, Swinnen JV, Smans K. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res. 2013;52:585–9.
Wang C, Rajput S, Watabe K, Liao D-F, Cao D. Acetyl-CoA carboxylase-a as a novel target for cancer therapy. Front Biosci Sch Ed. 2010;2:515–26.
Luo D-X, Tong D-J, Rajput S, Wang C, Liao D-F, Cao D, Maser E. Targeting acetyl-CoA carboxylases: small molecular inhibitors and their therapeutic potential. Recent Patents Anticancer Drug Discov. 2012;7:168–84.
Menendez JA, Lupu R. Fatty acid synthase regulates estrogen receptor-α signaling in breast cancer cells. Oncogenesis. 2017;6:e299.
Chajès V, Cambot M, Moreau K, Lenoir GM, Joulin V. Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res. 2006;66:5287–94.
Yoon S, Lee M-Y, Park SW, Moon J-S, Koh Y-K, Ahn Y-H, Park B-W, Kim K-S. Up-regulation of acetyl-CoA carboxylase α and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast Cancer cells. J Biol Chem. 2007;282:26122–31.
Minville-Walz M, Pierre A-S, Pichon L, Bellenger S, Fèvre C, Bellenger J, Tessier C, Narce M, Rialland M. Inhibition of Stearoyl-CoA desaturase 1 expression induces CHOP-dependent cell death in human Cancer cells. PLoS One. 2010;5(12):e14363.
Zhao J, Zhi Z, Wang C, Xing H, Song G, Yu X, Zhu Y, Wang X, Zhang X, Di Y. Exogenous lipids promote the growth of breast cancer cells via CD36. Oncol Rep. 2017;38:2105–15.
Welte MA. Expanding roles for lipid droplets. Curr Biol CB. 2015;25:R470–81.
Bozza PT, Viola JPB. Lipid droplets in inflammation and cancer. Prostaglandins Leukot Essent Fatty Acids. 2010;82:243–50.
Tirinato L, Liberale C, Di Franco S, Candeloro P, Benfante A, La Rocca R, Potze L, Marotta R, Ruffilli R, Rajamanickam VP, Malerba M, De Angelis F, Falqui A, Carbone E, Todaro M, Medema JP, Stassi G, Di Fabrizio E. Lipid droplets: a new player in colorectal Cancer stem cells unveiled by spectroscopic imaging. Stem Cells Dayt Ohio. 2015;33:35–44.
Abramczyk H, Surmacki J, Kopeć M, Olejnik AK, Lubecka-Pietruszewska K, Fabianowska-Majewska K. The role of lipid droplets and adipocytes in cancer. Raman imaging of cell cultures: MCF10A, MCF7, and MDA-MB-231 compared to adipocytes in cancerous human breast tissue. Analyst. 2015;140:2224–35.
Luu TH, Bard J-M, Carbonnelle D, Chaillou C, Huvelin J-M, Bobin-Dubigeon C, Nazih H. Lithocholic bile acid inhibits lipogenesis and induces apoptosis in breast cancer cells. Cell Oncol Dordr. 2018;41:13–24.
Smith B, Land H. Anticancer activity of the cholesterol exporter ABCA1 gene. Cell Rep. 2012;2:580–90.
Sánchez CA, Rodríguez E, Varela E, Zapata E, Páez A, Massó FA, Montaño LF, Lóopez-Marure R. Statin-induced inhibition of MCF-7 breast cancer cell proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated by an enhanced oxidative stress. Cancer Investig. 2008;26:698–707.
Ishikawa T, Hosaka YZ, Beckwitt C, Wells A, Oltvai ZN, Warita K. Concomitant attenuation of HMG-CoA reductase expression potentiates the cancer cell growth-inhibitory effect of statins and expands their efficacy in tumor cells with epithelial characteristics. Oncotarget. 2018;9:29304–15.
Griffett K, Solt LA, El-Gendy BE-DM, Kamenecka TM, Burris TP. A liver-selective LXR inverse agonist that suppresses hepatic steatosis. ACS Chem Biol. 2013;8:559–67.
El Roz A, Bard J-M, Valin S, Huvelin J-M, Nazih H. Macrophage apolipoprotein E and proliferation of MCF-7 breast cancer cells: role of LXR. Anticancer Res. 2013;33:3783–9.
Ju X, Huang P, Chen M, Wang Q. Liver X receptors as potential targets for cancer therapeutics. Oncol Lett. 2017;14:7676–80.
Murai T. The role of lipid rafts in Cancer cell adhesion and migration. Int J Cell Biol. 2012;2012:763283.
Carbonnelle D, Luu TH, Chaillou C, Huvelin J-M, Bard J-M, Nazih H. LXR activation Down-regulates lipid raft markers FLOT2 and DHHC5 in MCF-7 breast Cancer cells. Anticancer Res. 2017;37:4067–73.
Zhang Z, Wang L, Du J, Li Y, Yang H, Li C, Li H, Hu H. Lipid raft localization of epidermal growth factor receptor alters matrix metalloproteinase-1 expression in SiHa cells via the MAPK/ERK signaling pathway. Oncol Lett. 2016;12:4991–8.
Turk HF, Barhoumi R, Chapkin RS. Alteration of EGFR spatiotemporal dynamics suppresses signal transduction. PLoS One. 2012;7:e39682.
de Laurentiis A, Donovan L, Arcaro A. Lipid rafts and Caveolae in signaling by growth factor receptors. Open Biochem J. 2007;1:12–32.